DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
OwnerDavid Honeinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides DNA vaccines that direct the coincident expression of vaccine antigens coincidently with mutant ADP-ribosyltransferase toxins (mARTs), which display reduced, or are devoid of, ADP-ribosyltransferase activity, and methods for vaccinating animals with the same. In particular, the present invention provides DNA vaccines that direct the coincident expression of vaccine antigens and mARTs that are useful for vaccinating against viral, bacterial, parasitic pathogens, autoimmune antigens and transplantation antigens.
Claims20
A method of producing an immune response in a patient, comprising the steps of:
- introducing into said patient at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART) and at least one genetic sequence encoding an antigen;
- expressing said mART and said antigen after said introducing step.
An adjuvant, comprising one or more mutant ADP-ribosyltransferase toxins (mARTs).
An adjuvant, comprising a vector harboring an expressible genetic sequence encoding for a mutant ADP-ribosyltransferase toxin (mART).
A composition for producing an immune response, comprising:
- an antigen to which an immune response is desired;
- and
- an adjuvant in the form of one or more mutant ADP-ribosyltransferase toxins (mARTs).
A composition for producing an immune response, comprising:
- at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART);
- and
- at least one genetic sequence encoding an antigen, said mART functioning as an adjuvant for said antigen.
Dependencies are inferred from the claim text.